US Stock MarketDetailed Quotes

CANF Can-Fite BioPharma

Watchlist

2.2000
+0.1000+4.76%

Close Nov 29 13:00 ET

2.2300
+0.0300+1.36%

Post 15:55 ET

13.41MMarket Cap-846P/E (TTM)

Can-Fite BioPharma Stock Forum

Trytosaveabit

Nov 4 06:11

News

$Can-Fite BioPharma (CANF.US)$ Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
2 MINUTES AGO, 7:08 AM EST
VIA GLOBENEWSWIRE

Trytosaveabit

Oct 18 08:14

Update

$Can-Fite BioPharma (CANF.US)$ Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
7 MINUTES AGO, 9:06 AM EDT
VIA GLOBENEWSWIRE
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M

Trytosaveabit

Oct 9 14:25

$Can-Fite BioPharma (CANF.US)$ I knew you would make a move! Even if its a day late and low volume! And it even took a official 6K filing for people to believe! But in the end up is up🥂

Jaguar8

Oct 9 10:10

Have you decided to finally move?🤣

$Can-Fite BioPharma (CANF.US)$

Trytosaveabit

Oct 9 06:14

6K filed! Now maybe it will get attention? Hehehe

$Can-Fite BioPharma (CANF.US)$ 99.1
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the Company’s oncology drug candidate, Namodenoson, has been granted O...

Jaguar8

Oct 8 05:48

NEWS

$Can-Fite BioPharma (CANF.US)$
Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status

Trytosaveabit

Oct 8 05:41

Watching for FDA news!

$Can-Fite BioPharma (CANF.US)$ FDA’s Database says Orphan Drug status was granted for NAMODENOSON for Pancreatic Cancer on 10/7/2024! But i can’t access company website or find any PR

Trytosaveabit

Sep 16 06:07

Update

$Can-Fite BioPharma (CANF.US)$ Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
6 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE

Trytosaveabit

Jun 28 06:16

$Can-Fite BioPharma (CANF.US)$ Can-fite Biopharma Says Its Veterinary Partner Vetbiolix Reported Positive Results In An Osteoarthritis Multicenter Clinical Study In Dogs Treated With Piclidenoson

Stock Region

Jun 25 18:00

Biotechnology Firm Reveals Breakthrough Discovery For Anti-cancer Treatment

Can-Fite BioPharma: New Findings Highlight Namodenoson's Mechanism in Liver Protection and Cancer Treatment.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology firm dedicated to developing innovative treatments for oncological and inflammatory diseases, has unveiled new findings concerning its small molecule drug, Namodenoson. These recent discoveries shed light on the mechanisms by which Namodeno...

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data